Researchers in Brazil have engineered a new breed of cancer-fighting immune cells that show significantly better performance at destroying tumors, according to a study published in Frontiers in Immunology.
Scientists at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy used modified natural killer (NK) cells called NK-92 and equipped them with chimeric antigen receptors, or CARs. These specialized receptors were redesigned to include two critical components called 2B4 and DAP12, which essentially prime the cells for attack.
The addition of these signaling domains produced a measurable leap in performance. Cells engineered this way demonstrated substantially improved ability to target and eliminate tumor cells compared to standard versions of the therapy.
CAR-based immunotherapies have already revolutionized treatment for blood cancers, but researchers have struggled to fully understand what makes CAR-NK cells work optimally. This study addresses that knowledge gap by demonstrating which internal mechanisms trigger peak cell activation.
The team went further by combining the enhanced activation signals with temporary pharmaceutical control. They tested dasatinib, a drug that can briefly suppress cell activity, to determine whether controlled pauses might boost overall performance.
The strategy worked. When researchers paired the optimized 2B4-DAP12 signaling with dasatinib pretreatment, the engineered cells achieved superior tumor control in animal models. This suggests that balancing activation strength with reversible drug-based adjustments could lead to more powerful and adaptable cancer treatments down the road.
The implications point toward a next generation of CAR-NK therapies that offer both greater destructive capacity and finer operational control than current approaches.
Author Jessica Williams: "Arming natural killer cells with this level of precision and control could fundamentally change how we deploy immune therapy against solid tumors where standard CAR-T cells have struggled."
Comments